MSB - Most exciting 6 months, page-21

First 21 Last

Share
Profile

Follow
Kingtup

1,731 Posts.

193

21/05/20

14:36

Post #: 44752881
Share

Originally posted by danzae: ↑

I find it interesting that according to https://clinicaltrials.gov/ct2/show/NCT02032004
We are potentially 9 days away from an announcement of results of Revascor P3 trial - Chronic Heart Failure.
And yet rarely a word spoken of it.

It says a lot about MSB’s broadening potential that the excitement and anticipation is rather muted in comparison to ARDS.
This was inconceivable 6 months ago.

Personally I’ve been counting down the days for 4 months now. I’m excited but also tempering my expectations a little as the days tick by.
My only niggling concern, it’s now 111 days since the last patient visit and the results were unblinded.
If there was an overwhelming material difference in mortality rates (TCE’s) between the two test groups, I would have thought we may of heard by now.
For example, If most of the deaths occurred amongst the placebo group, surely we could have expected at least a headline data announcement - it would have been obvious to the researchers immediately the results were unblinded.

But the Phase2 results were strong so I keep the faith they can be replicated.
Even a 30% improvement should put a rocket under the SP. With Overwhelming efficiency, it’s fair to imagine that the SP could easily double overnight.
And this is before any partnership that would likely soon follow.

For most of us long-term holders, CHF and CLBP were the reasons we originally bought into MSB and why we held through all the dark years. This was going to be the ‘holy grail of the MSB portfolio.

I understand the current excitement re a possible treatment for ARDS, but CHF can also be company maker. If results are positive I'd guess every single shareholder will suddenly be well in profit.
Overwhelming results - will be a life changing moment for many of us.

Expand

can you remind me of the phase 2 results please

MSB Price at posting: $3.85 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 709 more messages in this thread...

First 21 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.48		Change 0.125(9.26%)		Mkt cap ! $1.644B

Open	High	Low	Value	Volume
$1.37	$1.48	$1.37	$12.51M	8.773M

Buyers (Bids)

No.	Vol.	Price($)
2	4035	$1.48

Sellers (Offers)

Price($)	Vol.	No.
$1.48	353057	14

View Market Depth

No.	Vol.	Price($)
5	10464	1.475
14	54753	1.470
10	81728	1.465
8	58156	1.460
7	25359	1.455

Price($)	Vol.	No.
1.480	302666	16
1.485	190631	9
1.490	196363	17
1.495	56847	12
1.500	247729	28

Last trade - 11.59am 04/10/2024 (20 minute delay)

MSB (ASX) Chart

MSB - Most exciting 6 months, page-21

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB - Most exciting 6 months, page-21

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News